bronchiectasis
BRONCHIECTASIS
Bronchiectasis is an irreversible pathologic dilatation or ectasia of the bronchi due to repeated airway infection and inflammation.
It enhances susceptibility to bronchial infection and increases inflammatory reaction which causes further lung damage.
Classic symptoms of of bronchiectasis are cough with chronic sputum production along with recurring infective exacerbations and hemoptysis.
  1. Bilton D, Tsang KW. Clinical challenges in managing bronchiectasis. Respirology. 2009 Jul;14(5):637-650. doi: 10.1111/j.1440-1843.2009.01569.x. Accessed 13 Jul 2010. PMID: 19659645
  2. Barker AF. Bronchiectasis. N Engl J Med. 2002 May;346(18):1383-1393. PMID: 11986413
  3. Canton R, Coll R, de Gracia J, et al. Diagnosis and treatment of bronchiectasis. Arch Bronconeumol. 2009;44:629-640. Accessed 13 Jul 2010
  4. Hacken NT, Kerstjens H, Postma D. Bronchiectasis. Clin Evid (Online). 2008 Jan:1507. PMID: 19450337
  5. Cohen M, Sahn SA. Bronchiectasis in systemic diseases. Chest. 1999 Oct;116(4):1063-1074. PMID: 10531174
  6. Chang AB, Grimwood K, Mulholland EK, et al. Bronchiectasis in indigenous children in remote Australian communities [position statement]. Med J Aust. 2002 Aug;177(4):200-204. PMID: 12175325
  7. Rosen MJ. Chronic cough due to bronchiectasis: ACCP evidence-based clinical practice guidelines. Chest. 2006 Jan;129(1)(Suppl):122S-131S. Accessed 13 Jul 2010. PMID: 16428701
  8. O'Donnell AE. Bronchiectasis. Chest. 2008 Oct;134(4):815-823. PMID: 18842914
  9. Kim DN, Lazarus AA. Management of bronchiectasis. Dis Mon. 2008 Aug;54(8):540-546. PMID: 18638622
  10. Tsang KW, Tipoe GL. Bronchiectasis: not an orphan disease in the East. Int J Tuberc Lung Dis. 2004 Jun;8(6):691-702. PMID: 15182138
  11. Tamaoki J, Chiyotani A, Kobayashi K, et al. Effect of indomethacin on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis, or bronchiectasis. Am Rev Respir Dis. 1992 Mar;145(3):548-552. PMID: 1546834
  12. Sherk PA , Grossman RF. The chronic obstructive pulmonary disease exacerbation. Clin Chest Med. 2000 Dec;21(4):705-721. PMID: 11194781
  13. Murray JF, Nadel JA. Bronchiectasis. Textbook of respiratory Medicine. 3rd ed. St Louis: W.B. Saunders Company; 2000:1325-1341
  14. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  15. MedWormhttp://www.medworm.com/rss/index.php/Respiratory-Medicine/40/http://www.medworm.com/rss/medicalfeeds/specialities/Respiratory-Medicine.xml
  16. Hassan I. Bronchiectasis. eMedicine. http://emedicine.medscape.com/article/296961-overview. Aug 2004. Accessed 10 Jun 2005
  17. Currie D. Differential diagnosis of bronchiectasis. Nov 2004. Accessed 10 Jun 2005
  18. Emmons E. Bronchiectasis: treatment and medication. eMedicine. http://emedicine.medscape.com/article/296961-treatment. Jun 2010. Accessed 13 Jul 2010
  19. Barker AF. Clinical manifestations and diagnosis of bronchiectasis in adults. UpToDate. http://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-bronchiectasis-in-adults. Nov 2004. Accessed 05 May 2005
  20. Barker AF. Treatment of bronchiectasis in adults. UpToDate. http://www.uptodate.com/contents/treatment-of-bronchiectasis-in-adults. Aug 2004. Accessed 05 May 2005
  21. Hill AT, Pasteur M, Cornford C, Welham S, Bilton D. Primary care summary of the British Thoracic Society Guideline on the management of non-cystic fibrosis bronchiectasis. Prim Care Respir J. 2011 Jun;20(2):135-140. http://www.thepcrj.org/journ/vol20/20_2_135_140.pdf. Accessed 18 Aug 2014. PMID: 21336465
  22. Pasteur MC, Bilton D, Hill AT; British Thoracic Society Non-CF Bronchiectasis Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010 Jul;65(7):577. https://www.brit-thoracic.org.uk/document-library/clinical-information/bronchiectasis/bts-guideline-for-non-cf-bronchiectasis/. Accessed 18 Aug 2014. PMID: 20627912
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 30 Apr 2019
A shorter regimen comprising a seven-drug cocktail which included high-dose moxifloxacin for 9 months was noninferior to the WHO*-recommended long regimen of 20 months for treating rifampicin-resistant tuberculosis (TB), according to the STREAM** study, providing a feasible and lower-cost treatment option in resource-poor setting.
31 Jan 2017
New drug applications approved by US FDA as of 16 - 31 January 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.